



# COVID-19 and Children's Surveillance Report

## Number 1

Compiled: 03 December 2021





# Contents

- Summary ..... 2
- List of abbreviations ..... 5
- Australia: Victoria ..... 6
- Australia: New South Wales..... 7
- Canada..... 8
- Denmark..... 9
- England, UK..... 10
- Finland ..... 11
- Scotland, UK..... 12
- Singapore ..... 13
- USA ..... 14
- USA: Comparison of states ..... 15
- USA: Impact of vaccination on disease incidence..... 18
- Authors..... 19





## Overview

- This weekly summary documents the latest COVID-19 surveillance data in children and adolescents, with a focus on Victoria and New South Wales (NSW) as well as specific countries that are relevant to the Australian context because of their size, COVID-19 epidemiology, the mitigation measures in place and data availability.
  - Data on Multisystem Inflammatory Syndrome in Children (MIS-C), or otherwise known as Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) was also searched for but is not always reported.
  - This report will be updated weekly using the most recently available data. South African data will be added next week.
  - The number of infections in unvaccinated children may also increase if school mitigation measures are few, there are changes to testing criteria and the adoption of screening in schools. The number of cases will be biased towards the age groups that are tested most.
- s

## Summary

- Throughout 2021, the proportion of infections in unvaccinated children has generally increased as vaccination of adults has increased.<sup>1,2</sup> This proportion may continue to increase as vaccines are not yet available for children under 12 years of age, except recently in the USA and several other countries.
- COVID-19 epidemiology in children and adolescents varies by setting.
- Following the return to school, many settings with high vaccination coverage and school mitigation measures have had few infections and outbreaks. Other settings with low coverage in all ages, including adolescents, and few mitigation measures have experienced an increase in case numbers in children and school outbreaks.
- Infections appear to be stable in Victoria and have declined in NSW with the return of face-to-face learning despite many school infections. This could be attributable to high vaccine coverage in ≥12 year olds and implementation of mitigation measures in schools including test, trace, isolate and quarantine (TTIQ).
- Victoria** opened all schools for onsite fulltime schooling on 1 November 2021. This followed a staggered return to in-person learning from 6 October, firstly with Year 12, followed by primary school years from 18 October. There are currently a total of ~1100 confirmed cases per day in all ages. There is no breakdown by age.
- In **New South Wales**, early childhood and education centres have been open throughout the entire Delta period. Despite this, the effective reproduction number (an estimate of how many people are infected by each positive case) has declined, which suggests young children contribute little to broader community transmission. Staged school re-opening for in-person learning started on 11 October and onsite fulltime schooling commenced on 8 November. The case numbers continue to show a downward trend in all age groups, including children.
- In **Canada**, where ~83% of 12-17 year olds are fully vaccinated, there has been no increase in cases in children aged 12+ years following schools reopening in early September. There was an initial steep increase in infections in 5-11 year olds after schools re-opened, but this is now declining. In the province of British Columbia, infections increased in children 5-11 years of age during the first two weeks of school reopening in September 2021, primarily in areas of lower vaccine coverage. Infections in this age group were trending downwards and now remain relatively stable. The increase in infections in September was partly due to a significant increase in testing among children. Serious illness in children has been rare in this province.
- In **Europe and North America**, schools returned after the summer break in September 2021.
- In **Denmark**, all mitigation measures in schools were lifted in early October 2021 except for a recommendation of weekly testing for staff and students aged 9 years and older who are unvaccinated. Some Public Health and Social Measures (PHSM) have been reintroduced due to a rise in COVID-19 cases, including indoor mask wearing and proof of vaccination to attend shops. In cases in all age groups from late September 2021 following return to school. Total infection and hospitalisation rates are on an upward trend.
- In **England**, following school re-opening, infections increased mostly in 12-15 years followed by primary school ages. Infection then decreased particularly in children 10-19 years of age, but also in children aged 5-9 years, before increasing slightly again. Infections in children aged 0-4 years remained amongst the lowest of most age groups. Vaccine uptake is low in 12-

### Summary of COVID-19 epidemiology in children and adolescents

Country	Cases	Hospitalisations	MIS-C/PIMS-TS	Total deaths <sup>^</sup>
VIC, Australia	↓*	Not available	Not available	2 <sup>b</sup>
NSW, Australia	↓	↓*	Not available	1 <sup>b</sup>
Canada	↓	↓	Not available	19 <sup>b</sup>
Denmark	↑	↑*	Not available	Not available
England, UK	Stable	↓	Not available	70 <sup>b</sup>
Finland	↑ 0-9y ↑ unvaccinated 12-19y	↑ but very low	Not available	0
Scotland, UK	Stable	Stable	Not available	3 <sup>a</sup>
Singapore	Stable	Stable	5 cases	0
USA	↓	↓	5973 cases	630 <sup>b</sup>

Note: Trends and values are for children only, unless otherwise specified.

\*Available data includes both children and adults.

<sup>^</sup>Age range for child deaths between 0-19y except Scotland (0-14y) and USA (0-17y). Deaths <sup>a</sup>due to COVID-19 or <sup>b</sup>with COVID-19.

<sup>1</sup> Russell FM, Anderson V, Crawford N, Curtis N, Danchin M, Goldfeld S, Hart J, Keeble T, Medley T, Mulholland K, Ranganathan S, Suryawijaya Ong D, Overmars I, Perrett K, Steer A. COVID-19 in Early Childhood Education and Care & Schools. Research Brief Number 1, Version 1: 14 October 2021. Parkville, Victoria, Australia: Murdoch Children’s Research Institute, The Royal Children’s Hospital, University of Melbourne Department of Paediatrics; 2021.

<sup>2</sup> American Academy of Pediatrics (AAP). Children and COVID-19: State-Level Data Report 14 October 2021. Illinois, US: AAP; 2021.



15 year olds (~42% single dose, which is the recommended schedule for this age group in the UK) and ~59.6% single dose in 16-17 year olds. Infections declined in children aged 5-19 years, following the extension of the vaccination program to 12-17 year olds in mid-September 2021. There was an initial increase in hospitalisations in the 5-14 year age group but this is now declining and rates in children this age remain the lowest compared to all other age groups. Mandatory mask wearing in shops and on public transport has been re-introduced due to an increase in COVID-19 cases across Europe. Close contacts who are fully vaccinated or under 18 years and 6 months of age and produce a negative PCR test result are not required to isolate.

- In **Finland**, which began vaccinating adolescents aged 12+ years in August 2021, there has been an increase in infections in under 19-year-olds after schools reopened in September and a small increase in hospitalisations amongst the unvaccinated in this age group, but rates remain very low. There were far fewer infections in the vaccinated compared to the unvaccinated.
- In **Scotland**, infections and hospitalisations increased in children with the return to in-person learning but then declined. There has been a total of three deaths due to COVID-19 amongst children aged 0-14y throughout the entire pandemic. Masks are recommended in secondary schools in Scotland. The country has vaccinated ~59% of 12-15 year olds with a single dose.
- In **Singapore**, schools re-opened with <70% total vaccine coverage in July 2021. Currently there are ~1200 cases per day and additional restrictions. There has been one ICU admission due to MIS-C and no deaths in children for the entire pandemic. A total of five cases of MIS-C have been reported, all from the current Delta wave. Primary schools were closed as a precautionary measure to ensure that primary school exams were not disrupted. There has been a phased return to schools from 11 October. Mitigation measures include vaccination of 12+ years, mask wearing, cohorting and screening with rapid antigen testing (RAT).
- In the **United States**, there are large differences in infection and hospitalisation rates in children between states due to differences in vaccination coverage and adherence to PHSM. Where there is high uptake of PHSM, such as in San Francisco, there are low infection and hospitalisation rates in children, and infections have declined in all age groups with school reopening. There is currently a downward trend in infections and hospitalisations in most US states including in unvaccinated children <12 years. There have been 630 deaths in children due to COVID-19 throughout the pandemic, accounting for <0.2% of all COVID-19 deaths in the US. Texas has had the highest number of child deaths (112) and there are 6 States that have reported 0 deaths throughout the entire pandemic. A total of 5973 cases of MIS-C have been reported, including 52 deaths.



## List of abbreviations

Abbreviation	Term
MIS-C	Multisystem inflammatory syndrome in children
NSW	New South Wales, Australia
PCR	Polymerase chain reaction
PHSM	Public health & social measures
PIMS-TS	Paediatric inflammatory multisystem syndrome
RAT	Rapid antigen testing
TTIQ	Test, trace, isolate, quarantine



## Australia: Victoria (population 6.6 million)

PHSM <sup>3</sup>	Schools & mitigation <sup>4</sup>	Vaccination coverage <sup>5</sup>																																																																																										
<p><b>As of 19 Nov 2021: Phase D</b> All gathering limits, capacity and density limits removed, masks only required in limited high-risk or low-vaccinated settings, onsite work can return for fully vaccinated people, all shops open, TTIQ, QR check-in, proof of vaccination to attend premises</p>	<p>All students returned to onsite fulltime schooling from 1 Nov 2021</p> <p>Standard PHSM, staggered return, cohorting, masks in primary &amp; secondary, mandatory vaccination for staff from 18 Oct, RAT available for students and staff who are close contacts at an educational setting, all educational contacts can return to school after a negative standard PCR following exposure</p> <p>Mandatory vaccination for staff</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> </tr> </thead> <tbody> <tr> <td>12-15</td> <td>87.0</td> <td>79.6</td> </tr> <tr> <td>16+</td> <td>93.4</td> <td>91.1</td> </tr> </tbody> </table> <p>Third dose for immunocompromised available from early Oct 2021, booster dose available to all eligible adults aged 18y+. Coverage data not available.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	12-15	87.0	79.6	16+	93.4	91.1																																																																																	
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)																																																																																										
12-15	87.0	79.6																																																																																										
16+	93.4	91.1																																																																																										
Infections by age group <sup>6</sup>	Hospitalisations in children <sup>7</sup>	Deaths by age group <sup>8</sup>																																																																																										
<p><b>Daily new cases in Victoria</b></p> <p><b>Cases by age group and gender</b></p> <table border="1"> <thead> <tr> <th>Age group</th> <th>All cases</th> <th>Active cases</th> </tr> </thead> <tbody> <tr><td>0-9</td><td>9,600</td><td>9,073</td></tr> <tr><td>10-19</td><td>9,636</td><td>9,264</td></tr> <tr><td>20-29</td><td>12,384</td><td>12,106</td></tr> <tr><td>30-39</td><td>10,623</td><td>10,070</td></tr> <tr><td>40-49</td><td>7,652</td><td>7,762</td></tr> <tr><td>50-59</td><td>5,681</td><td>5,969</td></tr> <tr><td>60-69</td><td>3,446</td><td>3,451</td></tr> <tr><td>70-79</td><td>1,999</td><td>1,903</td></tr> <tr><td>80-89</td><td>1,139</td><td>1,541</td></tr> <tr><td>90+</td><td>376</td><td>632</td></tr> <tr><td>Age unknown</td><td>4</td><td>1</td></tr> </tbody> </table>	Age group	All cases	Active cases	0-9	9,600	9,073	10-19	9,636	9,264	20-29	12,384	12,106	30-39	10,623	10,070	40-49	7,652	7,762	50-59	5,681	5,969	60-69	3,446	3,451	70-79	1,999	1,903	80-89	1,139	1,541	90+	376	632	Age unknown	4	1	<p><b>Current cases in hospital</b></p> <table border="1"> <tbody> <tr> <td>cases in hospital</td> <td><b>289</b></td> <td><b>43</b></td> </tr> <tr> <td></td> <td>cases in hospital</td> <td>cases in ICU</td> </tr> </tbody> </table> <p>No age breakdown</p> <p>Victorian hospitalisation and ICU counts exclude COVID-19 patients who are still in hospital but no longer infectious</p>	cases in hospital	<b>289</b>	<b>43</b>		cases in hospital	cases in ICU	<p><b>People who have passed away with COVID-19</b></p> <p>03/12/2021</p> <table border="1"> <thead> <tr> <th>Age group</th> <th>Male</th> <th>Female</th> <th>Total</th> </tr> </thead> <tbody> <tr><td>00-09</td><td>0</td><td>1</td><td>1</td></tr> <tr><td>10-19</td><td>0</td><td>1</td><td>1</td></tr> <tr><td>20-29</td><td>2</td><td>1</td><td>3</td></tr> <tr><td>30-39</td><td>4</td><td>0</td><td>4</td></tr> <tr><td>40-49</td><td>9</td><td>4</td><td>13</td></tr> <tr><td>50-59</td><td>33</td><td>19</td><td>52</td></tr> <tr><td>60-69</td><td>65</td><td>39</td><td>104</td></tr> <tr><td>70-79</td><td>175</td><td>106</td><td>281</td></tr> <tr><td>80-89</td><td>276</td><td>244</td><td>520</td></tr> <tr><td>90+</td><td>141</td><td>237</td><td>378</td></tr> <tr><td>Total</td><td>705</td><td>652</td><td>1,357</td></tr> </tbody> </table> <p>One 15 year old and one child under 10 with multiple underlying conditions and in palliative care died with COVID-19</p>	Age group	Male	Female	Total	00-09	0	1	1	10-19	0	1	1	20-29	2	1	3	30-39	4	0	4	40-49	9	4	13	50-59	33	19	52	60-69	65	39	104	70-79	175	106	281	80-89	276	244	520	90+	141	237	378	Total	705	652	1,357
Age group	All cases	Active cases																																																																																										
0-9	9,600	9,073																																																																																										
10-19	9,636	9,264																																																																																										
20-29	12,384	12,106																																																																																										
30-39	10,623	10,070																																																																																										
40-49	7,652	7,762																																																																																										
50-59	5,681	5,969																																																																																										
60-69	3,446	3,451																																																																																										
70-79	1,999	1,903																																																																																										
80-89	1,139	1,541																																																																																										
90+	376	632																																																																																										
Age unknown	4	1																																																																																										
cases in hospital	<b>289</b>	<b>43</b>																																																																																										
	cases in hospital	cases in ICU																																																																																										
Age group	Male	Female	Total																																																																																									
00-09	0	1	1																																																																																									
10-19	0	1	1																																																																																									
20-29	2	1	3																																																																																									
30-39	4	0	4																																																																																									
40-49	9	4	13																																																																																									
50-59	33	19	52																																																																																									
60-69	65	39	104																																																																																									
70-79	175	106	281																																																																																									
80-89	276	244	520																																																																																									
90+	141	237	378																																																																																									
Total	705	652	1,357																																																																																									

<sup>3</sup> <https://www.coronavirus.vic.gov.au/coronavirus-covidsafe-settings>

<sup>4</sup> <https://www.coronavirus.vic.gov.au/education-information-about-coronavirus-covid-19>

<sup>5</sup> <https://www.health.gov.au/resources/collections/covid-19-vaccination-daily-rollout-update>

<sup>6</sup> <https://www.coronavirus.vic.gov.au/victorian-coronavirus-covid-19-data>

<sup>7</sup> <https://www.coronavirus.vic.gov.au/victorian-coronavirus-covid-19-data>

<sup>8</sup> <https://www.coronavirus.vic.gov.au/additional-covid-19-case-data#cases-in-hospital>










# Australia: New South Wales (population 8.2 million)

PHSM <sup>9</sup>	Schools & mitigation <sup>10,11</sup>	Vaccination coverage <sup>12</sup>																																																																																																																																																																																																													
<p>Mandatory masks indoors and on public transport, TTIQ, QR check-in, all shops open</p> <p><b>Vaccinated people:</b> Proof of vaccination to attend premises</p> <p><b>Not fully vaccinated:</b> No visitors at home with exceptions, attendance in shops limited to essential services only</p>	<p>All students returned to onsite fulltime schooling from 8 Nov 2021</p> <p>Standard PHSM, RAT home testing for educational contacts</p> <p>Mandatory vaccination for staff from 8 Nov 2021</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> </tr> </thead> <tbody> <tr> <td>12-15</td> <td>81.4</td> <td>77.0</td> </tr> <tr> <td>16+</td> <td>94.6</td> <td>92.7</td> </tr> </tbody> </table> <p>Third dose for immunocompromised available from early Oct 2021, booster dose available to all eligible adults aged 18y+. Coverage data not available.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	12-15	81.4	77.0	16+	94.6	92.7																																																																																																																																																																																																				
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)																																																																																																																																																																																																													
12-15	81.4	77.0																																																																																																																																																																																																													
16+	94.6	92.7																																																																																																																																																																																																													
Infections by age group <sup>13</sup>	Hospitalisations in children <sup>14</sup>	Deaths by age group <sup>15</sup>																																																																																																																																																																																																													
<p>Figure 5. Seven day backward rolling average of COVID-19 cases rate per 100,000 population by age and notification date, NSW, from 16 June 2021 to 20 November 2021</p>	<p>Hospitalisations among people diagnosed with COVID-19, by age group, NSW</p> <table border="1"> <thead> <tr> <th rowspan="2">Age-group (years)</th> <th colspan="3">Since 16 Jun 2021</th> <th colspan="2">Jan 2020 – 15 Jun 2021</th> </tr> <tr> <th>Hospitalised</th> <th>Percentage of cases hospitalised<sup>1</sup></th> <th>Hospitalised per 100,000 population</th> <th>Hospitalised</th> <th>Percentage of cases hospitalised<sup>1</sup></th> </tr> </thead> <tbody> <tr><td>0-9</td><td>402</td><td>3%</td><td>39.8</td><td>4</td><td>2%</td></tr> <tr><td>10-19</td><td>503</td><td>4%</td><td>52.2</td><td>10</td><td>3%</td></tr> <tr><td>20-29</td><td>1,293</td><td>9%</td><td>110.3</td><td>27</td><td>2%</td></tr> <tr><td>30-39</td><td>1,558</td><td>12%</td><td>133.1</td><td>46</td><td>4%</td></tr> <tr><td>40-49</td><td>1,485</td><td>16%</td><td>143.8</td><td>48</td><td>7%</td></tr> <tr><td>50-59</td><td>1,411</td><td>21%</td><td>145.1</td><td>78</td><td>11%</td></tr> <tr><td>60-69</td><td>1,113</td><td>29%</td><td>132.4</td><td>117</td><td>18%</td></tr> <tr><td>70-79</td><td>782</td><td>42%</td><td>134.2</td><td>92</td><td>23%</td></tr> <tr><td>80-89</td><td>518</td><td>56%</td><td>188.9</td><td>52</td><td>43%</td></tr> <tr><td>90+</td><td>125</td><td>54%</td><td>180.2</td><td>16</td><td>38%</td></tr> <tr><td>Total</td><td>9,190</td><td>12%</td><td>113.6</td><td>490</td><td>9%</td></tr> </tbody> </table> <p>Figure 7b. Number of cases in hospital, in ICU and ventilated by date, NSW, from 16 June to 20 November 2021</p> <p>Majority of admissions in &lt;12y children are for social reasons as parents are hospitalised for treatment of COVID-19</p> <p>Graph is not available by age group</p>	Age-group (years)	Since 16 Jun 2021			Jan 2020 – 15 Jun 2021		Hospitalised	Percentage of cases hospitalised <sup>1</sup>	Hospitalised per 100,000 population	Hospitalised	Percentage of cases hospitalised <sup>1</sup>	0-9	402	3%	39.8	4	2%	10-19	503	4%	52.2	10	3%	20-29	1,293	9%	110.3	27	2%	30-39	1,558	12%	133.1	46	4%	40-49	1,485	16%	143.8	48	7%	50-59	1,411	21%	145.1	78	11%	60-69	1,113	29%	132.4	117	18%	70-79	782	42%	134.2	92	23%	80-89	518	56%	188.9	52	43%	90+	125	54%	180.2	16	38%	Total	9,190	12%	113.6	490	9%	<p>Table 5. Deaths following recent infection with COVID-19, by age group, from January 2020 to 20 November 2021</p> <table border="1"> <thead> <tr> <th rowspan="2">Age-group (years)</th> <th colspan="3">Since 16 Jun 2021</th> <th colspan="2">Jan 2020 – 15 Jun 2021</th> </tr> <tr> <th>Number of deaths</th> <th>Case fatality rate</th> <th>Fatality rate per 100,000 population<sup>3</sup></th> <th>Number of deaths</th> <th>Case fatality rate<sup>2</sup></th> </tr> </thead> <tbody> <tr><td>0-9</td><td>0</td><td>0%</td><td>0.0</td><td>0</td><td>0%</td></tr> <tr><td>10-19</td><td>1</td><td>&lt;1%</td><td>0.1</td><td>0</td><td>0%</td></tr> <tr><td>20-29</td><td>6</td><td>&lt;1%</td><td>0.5</td><td>0</td><td>0%</td></tr> <tr><td>30-39</td><td>15</td><td>&lt;1%</td><td>1.3</td><td>0</td><td>0%</td></tr> <tr><td>40-49</td><td>26</td><td>&lt;1%</td><td>2.5</td><td>0</td><td>0%</td></tr> <tr><td>50-59</td><td>63</td><td>1%</td><td>6.5</td><td>1</td><td>&lt;1%</td></tr> <tr><td>60-69</td><td>100</td><td>3%</td><td>11.9</td><td>4</td><td>1%</td></tr> <tr><td>70-79</td><td>132</td><td>7%</td><td>22.7</td><td>15</td><td>4%</td></tr> <tr><td>80-89</td><td>161</td><td>17%</td><td>58.7</td><td>20</td><td>16%</td></tr> <tr><td>90+</td><td>62</td><td>27%</td><td>89.4</td><td>16</td><td>38%</td></tr> <tr><td>Total</td><td>566</td><td>1%</td><td>7.0</td><td>56</td><td>1%</td></tr> </tbody> </table> <p>Proportion of cases with a severe outcome (ICU and/or death) amongst all cases, by age, time of infection, and vaccination status</p> <table border="1"> <thead> <tr> <th rowspan="2">Age-group (years)</th> <th colspan="3">% cases with severe outcomes (ICU and/or death)</th> </tr> <tr> <th>Jan 2020 - 15 Jun 2021</th> <th>16 Jun - 20 Nov 2021: Fully vaccinated</th> <th>16 Jun - 20 Nov 2021: Un-vaccinated</th> </tr> </thead> <tbody> <tr><td>0-9</td><td>0% (0 / 251)</td><td>-</td><td>&lt;1% (9 / 12,187)</td></tr> <tr><td>10-19</td><td>&lt;1% (1 / 325)</td><td>0% (0 / 137)</td><td>&lt;1% (27 / 9,487)</td></tr> <tr><td>20-29</td><td>&lt;1% (4 / 1,115)</td><td>&lt;1% (2 / 940)</td><td>1% (98 / 9,692)</td></tr> <tr><td>30-39</td><td>1% (15 / 1,098)</td><td>&lt;1% (4 / 1,285)</td><td>2% (154 / 7,709)</td></tr> <tr><td>40-49</td><td>2% (12 / 718)</td><td>&lt;1% (4 / 1,198)</td><td>3% (176 / 5,298)</td></tr> <tr><td>50-59</td><td>4% (30 / 710)</td><td>1% (15 / 1,078)</td><td>7% (258 / 3,647)</td></tr> <tr><td>60-69</td><td>7% (44 / 656)</td><td>2% (17 / 768)</td><td>13% (228 / 1,730)</td></tr> <tr><td>70-79</td><td>12% (46 / 394)</td><td>6% (33 / 532)</td><td>24% (161 / 683)</td></tr> <tr><td>80-89</td><td>21% (26 / 122)</td><td>11% (33 / 288)</td><td>36% (126 / 349)</td></tr> <tr><td>90+</td><td>38% (16 / 42)</td><td>21% (24 / 113)</td><td>45% (28 / 62)</td></tr> <tr><td>Total</td><td>4% (194 / 5,431)</td><td>2% (132 / 6,339)</td><td>2% (1,265 / 50,844)</td></tr> </tbody> </table> <p>* For this table, un-vaccinated includes those with no effective dose, and those who are ineligible for vaccination (aged 0-11 years).</p> <p>One 15 year old died with pneumococcal meningitis and COVID-19</p>	Age-group (years)	Since 16 Jun 2021			Jan 2020 – 15 Jun 2021		Number of deaths	Case fatality rate	Fatality rate per 100,000 population <sup>3</sup>	Number of deaths	Case fatality rate <sup>2</sup>	0-9	0	0%	0.0	0	0%	10-19	1	<1%	0.1	0	0%	20-29	6	<1%	0.5	0	0%	30-39	15	<1%	1.3	0	0%	40-49	26	<1%	2.5	0	0%	50-59	63	1%	6.5	1	<1%	60-69	100	3%	11.9	4	1%	70-79	132	7%	22.7	15	4%	80-89	161	17%	58.7	20	16%	90+	62	27%	89.4	16	38%	Total	566	1%	7.0	56	1%	Age-group (years)	% cases with severe outcomes (ICU and/or death)			Jan 2020 - 15 Jun 2021	16 Jun - 20 Nov 2021: Fully vaccinated	16 Jun - 20 Nov 2021: Un-vaccinated	0-9	0% (0 / 251)	-	<1% (9 / 12,187)	10-19	<1% (1 / 325)	0% (0 / 137)	<1% (27 / 9,487)	20-29	<1% (4 / 1,115)	<1% (2 / 940)	1% (98 / 9,692)	30-39	1% (15 / 1,098)	<1% (4 / 1,285)	2% (154 / 7,709)	40-49	2% (12 / 718)	<1% (4 / 1,198)	3% (176 / 5,298)	50-59	4% (30 / 710)	1% (15 / 1,078)	7% (258 / 3,647)	60-69	7% (44 / 656)	2% (17 / 768)	13% (228 / 1,730)	70-79	12% (46 / 394)	6% (33 / 532)	24% (161 / 683)	80-89	21% (26 / 122)	11% (33 / 288)	36% (126 / 349)	90+	38% (16 / 42)	21% (24 / 113)	45% (28 / 62)	Total	4% (194 / 5,431)	2% (132 / 6,339)	2% (1,265 / 50,844)
Age-group (years)	Since 16 Jun 2021			Jan 2020 – 15 Jun 2021																																																																																																																																																																																																											
	Hospitalised	Percentage of cases hospitalised <sup>1</sup>	Hospitalised per 100,000 population	Hospitalised	Percentage of cases hospitalised <sup>1</sup>																																																																																																																																																																																																										
0-9	402	3%	39.8	4	2%																																																																																																																																																																																																										
10-19	503	4%	52.2	10	3%																																																																																																																																																																																																										
20-29	1,293	9%	110.3	27	2%																																																																																																																																																																																																										
30-39	1,558	12%	133.1	46	4%																																																																																																																																																																																																										
40-49	1,485	16%	143.8	48	7%																																																																																																																																																																																																										
50-59	1,411	21%	145.1	78	11%																																																																																																																																																																																																										
60-69	1,113	29%	132.4	117	18%																																																																																																																																																																																																										
70-79	782	42%	134.2	92	23%																																																																																																																																																																																																										
80-89	518	56%	188.9	52	43%																																																																																																																																																																																																										
90+	125	54%	180.2	16	38%																																																																																																																																																																																																										
Total	9,190	12%	113.6	490	9%																																																																																																																																																																																																										
Age-group (years)	Since 16 Jun 2021			Jan 2020 – 15 Jun 2021																																																																																																																																																																																																											
	Number of deaths	Case fatality rate	Fatality rate per 100,000 population <sup>3</sup>	Number of deaths	Case fatality rate <sup>2</sup>																																																																																																																																																																																																										
0-9	0	0%	0.0	0	0%																																																																																																																																																																																																										
10-19	1	<1%	0.1	0	0%																																																																																																																																																																																																										
20-29	6	<1%	0.5	0	0%																																																																																																																																																																																																										
30-39	15	<1%	1.3	0	0%																																																																																																																																																																																																										
40-49	26	<1%	2.5	0	0%																																																																																																																																																																																																										
50-59	63	1%	6.5	1	<1%																																																																																																																																																																																																										
60-69	100	3%	11.9	4	1%																																																																																																																																																																																																										
70-79	132	7%	22.7	15	4%																																																																																																																																																																																																										
80-89	161	17%	58.7	20	16%																																																																																																																																																																																																										
90+	62	27%	89.4	16	38%																																																																																																																																																																																																										
Total	566	1%	7.0	56	1%																																																																																																																																																																																																										
Age-group (years)	% cases with severe outcomes (ICU and/or death)																																																																																																																																																																																																														
	Jan 2020 - 15 Jun 2021	16 Jun - 20 Nov 2021: Fully vaccinated	16 Jun - 20 Nov 2021: Un-vaccinated																																																																																																																																																																																																												
0-9	0% (0 / 251)	-	<1% (9 / 12,187)																																																																																																																																																																																																												
10-19	<1% (1 / 325)	0% (0 / 137)	<1% (27 / 9,487)																																																																																																																																																																																																												
20-29	<1% (4 / 1,115)	<1% (2 / 940)	1% (98 / 9,692)																																																																																																																																																																																																												
30-39	1% (15 / 1,098)	<1% (4 / 1,285)	2% (154 / 7,709)																																																																																																																																																																																																												
40-49	2% (12 / 718)	<1% (4 / 1,198)	3% (176 / 5,298)																																																																																																																																																																																																												
50-59	4% (30 / 710)	1% (15 / 1,078)	7% (258 / 3,647)																																																																																																																																																																																																												
60-69	7% (44 / 656)	2% (17 / 768)	13% (228 / 1,730)																																																																																																																																																																																																												
70-79	12% (46 / 394)	6% (33 / 532)	24% (161 / 683)																																																																																																																																																																																																												
80-89	21% (26 / 122)	11% (33 / 288)	36% (126 / 349)																																																																																																																																																																																																												
90+	38% (16 / 42)	21% (24 / 113)	45% (28 / 62)																																																																																																																																																																																																												
Total	4% (194 / 5,431)	2% (132 / 6,339)	2% (1,265 / 50,844)																																																																																																																																																																																																												

<sup>9</sup> <https://www.nsw.gov.au/covid-19/stay-safe/rules>  
<sup>10</sup> <https://education.nsw.gov.au/covid-19/advice-for-families/vaccination-requirements-for-school-sites>  
<sup>11</sup> <https://education.nsw.gov.au/covid-19/advice-for-families>  
<sup>12</sup> <https://www.health.gov.au/resources/collections/covid-19-vaccination-daily-rollout-update>  
<sup>13</sup> <https://www.health.nsw.gov.au/Infectious/covid-19/Pages/weekly-reports.aspx>  
<sup>14</sup> <https://www.health.nsw.gov.au/Infectious/covid-19/Pages/weekly-reports.aspx>  
<sup>15</sup> <https://www.health.nsw.gov.au/Infectious/covid-19/Pages/weekly-reports.aspx>



# Canada (population 38 million)

PHSM <sup>16</sup>	Schools & mitigation <sup>17</sup>	Vaccination coverage <sup>18</sup>									
<p>Standard PHSM including TTIQ and mask wearing encouraged in shared spaces and subject to local advice</p>  <p>Figure 3. COVID-19 cases (n=1,727,148) in Canada by date as of November 26, 2021, 7 pm EST (by age - 10 year groups)</p>	<p>Re-opened in Sep 2021 Standard PHSM and additional measures depending on local advice: physical distancing, cohorting, masks when required, screening tests Vaccination of 12y+ commenced mid-May 2021</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>Fully vaccinated* (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>89.3</td> <td>86.0</td> </tr> <tr> <td>12-17</td> <td>87.6</td> <td>82.7</td> </tr> </tbody> </table> <p>*Canada also uses the J&amp;J/ Janssen vaccine which is a single-dose vaccine. Third/booster doses have been available to high-risk individuals in phases since Sep 2021, coverage data not available.</p>	Age group (years)	1 <sup>st</sup> dose (%)	Fully vaccinated* (%)	12+	89.3	86.0	12-17	87.6	82.7
Age group (years)	1 <sup>st</sup> dose (%)	Fully vaccinated* (%)									
12+	89.3	86.0									
12-17	87.6	82.7									
Infections by age group <sup>19,20</sup>	Hospitalisations in children <sup>21</sup>	Deaths by age group <sup>22</sup>									
 <p>Figure 5. Distribution of confirmed COVID-19 cases reported to PHAC by vaccination status as of November 13, 2021</p>	 <p>Figure 7. Age and gender distribution of COVID-19 cases (hospitalized) in Canada as of November 26, 2021, 7 pm EST (n=91,895)</p>	 <p>Figure 7. Age and gender distribution of COVID-19 cases (deceased) in Canada as of November 26, 2021, 7 pm EST (n=29,390)</p>									
<p>British Columbia (pop. 5.1 million):</p>  <p>Figure 4. Current summary of pediatric COVID-19 cases and outcomes, vaccine coverage, school notifications, and school case clusters in BC, as of November 2021</p>  <p>Figure 5. Rate of COVID-19 cases by age group, BC, January 1 to November 16, 2021</p>	 <p>Figure 6. Daily number of hospital beds and ICU beds occupied by COVID-19 patients as of November 29, 2021</p>	<p>There have been 19 deaths with COVID-19 in children aged 0-19y throughout the pandemic</p>									

<sup>16</sup> <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html>  
<sup>17</sup> <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/planning-2021-2022-school-year-vaccination.html>  
<sup>18</sup> <https://health-infobase.canada.ca/covid-19/vaccination-coverage/>  
<sup>19</sup> <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>  
<sup>20</sup> <http://www.bccdc.ca/schools/news-resources/data-for-k12>  
<sup>21</sup> <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>  
<sup>22</sup> <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>



# Denmark

(population 5.9 million)

PHSM <sup>23</sup>	Schools & mitigation <sup>24</sup>	Vaccination coverage <sup>25</sup>																																																																																											
<p>Reinstatement of certain measures in late Nov 2021, including indoor mask wearing and digital pass (proof of vaccination or negative COVID-19 test) for shops and restaurants</p> <p>Previously all PHSM lifted on 8 Oct 2021, except for mask wearing in airports &amp; hospitals</p>	<p>Re-opened in May 2021</p> <p>Standard PHSM; PCR or RAT screening tests: Recommended weekly for staff &amp; students from grade 1 unless fully vaccinated or previously infected with COVID-19 in the last 12 months, twice weekly tests recommended for areas with high infection rates</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>77.9</td> <td>75.9</td> </tr> </tbody> </table> <p>Commenced 3<sup>rd</sup>/booster vaccination for people 65+y in late Oct 2021 and for all adults from late Nov, coverage data not available. Vaccination for 5-11y age group commenced late Nov 2021, coverage data not available.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	12+	77.9	75.9																																																																																					
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)																																																																																											
12+	77.9	75.9																																																																																											
Infections by age group <sup>26</sup>	Hospitalisations in children <sup>27,28</sup>	Deaths by age group <sup>29</sup>																																																																																											
<p>Denmark: 14-day age-specific COVID-19 case notification rate</p> <p>Source: ECDC COVID-19</p>	<table border="1"> <thead> <tr> <th>Age group</th> <th>Confirmed cases</th> <th>Total hospitalised (%)</th> <th>Comorbid. (%)</th> <th>Short hospital stay</th> <th>Hospitalised females</th> <th>Hospitalised males</th> </tr> <tr> <th>Aldersgrupper</th> <th>Bekræftede tilfælde</th> <th>Indlagte i alt (%)</th> <th>Heraf med komorbiditet (%)</th> <th>Korte indlæggelser**</th> <th>Indlagte kvinder</th> <th>Indlagte mænd</th> </tr> </thead> <tbody> <tr> <td>0-9</td> <td>50.037</td> <td>408 (1)</td> <td>87 (21)</td> <td>188</td> <td>190</td> <td>218</td> </tr> <tr> <td>10-19</td> <td>84.839</td> <td>378 (0)</td> <td>112 (30)</td> <td>139</td> <td>212</td> <td>166</td> </tr> <tr> <td>20-29</td> <td>93.713</td> <td>1.291 (1)</td> <td>500 (39)</td> <td>474</td> <td>790</td> <td>501</td> </tr> <tr> <td>30-39</td> <td>68.128</td> <td>1.816 (3)</td> <td>735 (40)</td> <td>635</td> <td>1.058</td> <td>758</td> </tr> <tr> <td>40-49</td> <td>69.170</td> <td>2.278 (3)</td> <td>1.027 (45)</td> <td>679</td> <td>1.114</td> <td>1.164</td> </tr> <tr> <td>50-59</td> <td>58.210</td> <td>3.062 (5)</td> <td>1.716 (56)</td> <td>654</td> <td>1.362</td> <td>1.700</td> </tr> <tr> <td>60-69</td> <td>32.010</td> <td>2.960 (9)</td> <td>2.050 (69)</td> <td>413</td> <td>1.198</td> <td>1.762</td> </tr> <tr> <td>70-79</td> <td>20.447</td> <td>4.054 (20)</td> <td>3.387 (84)</td> <td>353</td> <td>1.690</td> <td>2.364</td> </tr> <tr> <td>80-89</td> <td>8.563</td> <td>3.207 (37)</td> <td>2.811 (88)</td> <td>259</td> <td>1.576</td> <td>1.631</td> </tr> <tr> <td>90+</td> <td>2.284</td> <td>859 (38)</td> <td>771 (90)</td> <td>55</td> <td>499</td> <td>360</td> </tr> <tr> <td><b>I alt</b></td> <td><b>487.401</b></td> <td><b>20.313 (4)</b></td> <td><b>13.196 (65)</b></td> <td><b>3849</b></td> <td><b>9.689</b></td> <td><b>10.624</b></td> </tr> </tbody> </table> <p>Denmark: rate of new hospital COVID-19 admissions</p> <p>Source: ECDC database compiled from public online sources</p> <p>For the entire pandemic, a total of 33 children in ICU, which included 11 children with comorbidities</p> <p>Graph is not available by age group</p>	Age group	Confirmed cases	Total hospitalised (%)	Comorbid. (%)	Short hospital stay	Hospitalised females	Hospitalised males	Aldersgrupper	Bekræftede tilfælde	Indlagte i alt (%)	Heraf med komorbiditet (%)	Korte indlæggelser**	Indlagte kvinder	Indlagte mænd	0-9	50.037	408 (1)	87 (21)	188	190	218	10-19	84.839	378 (0)	112 (30)	139	212	166	20-29	93.713	1.291 (1)	500 (39)	474	790	501	30-39	68.128	1.816 (3)	735 (40)	635	1.058	758	40-49	69.170	2.278 (3)	1.027 (45)	679	1.114	1.164	50-59	58.210	3.062 (5)	1.716 (56)	654	1.362	1.700	60-69	32.010	2.960 (9)	2.050 (69)	413	1.198	1.762	70-79	20.447	4.054 (20)	3.387 (84)	353	1.690	2.364	80-89	8.563	3.207 (37)	2.811 (88)	259	1.576	1.631	90+	2.284	859 (38)	771 (90)	55	499	360	<b>I alt</b>	<b>487.401</b>	<b>20.313 (4)</b>	<b>13.196 (65)</b>	<b>3849</b>	<b>9.689</b>	<b>10.624</b>	<p>Total of 2912 in all age groups, but no age breakdown</p>
Age group	Confirmed cases	Total hospitalised (%)	Comorbid. (%)	Short hospital stay	Hospitalised females	Hospitalised males																																																																																							
Aldersgrupper	Bekræftede tilfælde	Indlagte i alt (%)	Heraf med komorbiditet (%)	Korte indlæggelser**	Indlagte kvinder	Indlagte mænd																																																																																							
0-9	50.037	408 (1)	87 (21)	188	190	218																																																																																							
10-19	84.839	378 (0)	112 (30)	139	212	166																																																																																							
20-29	93.713	1.291 (1)	500 (39)	474	790	501																																																																																							
30-39	68.128	1.816 (3)	735 (40)	635	1.058	758																																																																																							
40-49	69.170	2.278 (3)	1.027 (45)	679	1.114	1.164																																																																																							
50-59	58.210	3.062 (5)	1.716 (56)	654	1.362	1.700																																																																																							
60-69	32.010	2.960 (9)	2.050 (69)	413	1.198	1.762																																																																																							
70-79	20.447	4.054 (20)	3.387 (84)	353	1.690	2.364																																																																																							
80-89	8.563	3.207 (37)	2.811 (88)	259	1.576	1.631																																																																																							
90+	2.284	859 (38)	771 (90)	55	499	360																																																																																							
<b>I alt</b>	<b>487.401</b>	<b>20.313 (4)</b>	<b>13.196 (65)</b>	<b>3849</b>	<b>9.689</b>	<b>10.624</b>																																																																																							

<sup>23</sup> <https://en.coronasmitte.dk/rules-and-regulations>  
<sup>24</sup> <https://en.coronasmitte.dk/rules-and-regulations>  
<sup>25</sup> [https://experience.arcgis.com/experience/9824b03b114244348ef0b10f69f490b4/page/page\\_3/](https://experience.arcgis.com/experience/9824b03b114244348ef0b10f69f490b4/page/page_3/)  
<sup>26</sup> <https://covid19-country-overviews.ecdc.europa.eu/countries/Denmark.html>  
<sup>27</sup> <https://www.sst.dk/da/corona/tal-og-overvaagning>  
<sup>28</sup> <https://covid19-country-overviews.ecdc.europa.eu/countries/Denmark.html>  
<sup>29</sup> <https://www.sst.dk/da/corona/tal-og-overvaagning>





# England, UK

(population 56.6 million)

PHSM <sup>30</sup>	Schools & mitigation <sup>31</sup>	Vaccination coverage <sup>32</sup>																
<p>Standard PHSM including TTIQ and mandatory mask wearing in shops and on public transport</p> <p>Previously most PHSM lifted until re-introduced in late Nov 2021</p>	<p>Re-opened after summer holiday in mid-Sep 2021</p> <p>Standard PHSM, cohorting, mask wearing recommended for adults and students from year 7 onwards, twice-weekly RAT screening for staff and secondary school students, vaccination of 16-17y commenced mid-Aug &amp; 12-15y commenced mid-Sep 2021 (single dose)</p> <p>Close contacts who are fully vaccinated or under 18.5y and produce a negative PCR test result do not need to isolate</p>	<p><b>Age group</b></p> <table border="1"> <thead> <tr> <th>(years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> <th>3<sup>rd</sup>/booster (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>88.5</td> <td>80.5</td> <td>32.9</td> </tr> <tr> <td>12-15</td> <td>42.3</td> <td>0.6</td> <td>-</td> </tr> <tr> <td>16-17</td> <td>59.6</td> <td>19.8</td> <td>0.8</td> </tr> </tbody> </table> <p>Third/booster dose for 40y+ and other high-risk individuals, commenced Sep 2021.</p>	(years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)	12+	88.5	80.5	32.9	12-15	42.3	0.6	-	16-17	59.6	19.8	0.8
(years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)															
12+	88.5	80.5	32.9															
12-15	42.3	0.6	-															
16-17	59.6	19.8	0.8															
<p><b>Infections by age group<sup>33,34</sup></b></p> <p>Figure 5: Weekly confirmed COVID-19 case rates per 100,000, tested under Pillar 1 and Pillar 2, by age group</p> <p>Figure 4: The percentage of people testing positive for COVID-19 increased for those in school Year 12 up to age 34 years in the week ending 20 November 2021</p> <p>Estimated daily percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs by age group, England, 10 October to 20 November 2021</p>	<p><b>Hospitalisations in children<sup>35,36</sup></b></p> <p>Figure 43: Weekly hospital admission rate by age group for new (a) COVID-19 positive cases and (b) influenza reported through SARI Watch</p> <p>Hospital admissions are 33% higher for those aged 5 to 14 years than in January 2021</p> <p>COVID-19-positive hospital admissions as a percentage of the rate during the January peak (rate in week ending 17 January = 100%), by age, England</p>	<p><b>Deaths by age group<sup>37</sup></b></p> <p>Figure 55: Age-sex pyramid of laboratory confirmed COVID-19 deaths, for the past year</p> <p>Deaths with COVID-19 in the past year:</p> <ul style="list-style-type: none"> <li>&lt;5y: 13</li> <li>5-9y: 8</li> <li>10-19y: 49</li> </ul>																

<sup>30</sup> <https://www.gov.uk/guidance/covid-19-coronavirus-restrictions-what-you-can-and-cannot-do>  
<sup>31</sup> <https://www.gov.uk/government/publications/actions-for-schools-during-the-coronavirus-outbreak/schools-covid-19-operational-guidance>  
<sup>32</sup> <https://coronavirus.data.gov.uk/details/vaccinations?areaType=nation&areaName=England>  
<sup>33</sup> <https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season>  
<sup>34</sup> <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurvey/pilot/previousReleases>  
<sup>35</sup> <https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season>  
<sup>36</sup> <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19lateinsights/hospitals>  
<sup>37</sup> <https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season>



# Finland

(population 5.5 million)

PHSM <sup>38</sup>	Schools & mitigation <sup>39</sup>	Vaccination coverage <sup>40,41</sup>																
<p>Mask wearing encouraged in crowded areas, TTIQ, physical distancing, hand hygiene and respiratory etiquette</p>	<p>Many schools have reopened from Sep 2021</p> <p>Standard PHSM, cohorting, masks, vaccination of 12y+ commenced early Aug 2021</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> <th>3<sup>rd</sup>/booster (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>86.8</td> <td>81.9</td> <td>6.0</td> </tr> <tr> <td>12-15</td> <td>75.0</td> <td>64.8</td> <td>0.2</td> </tr> <tr> <td>16-19</td> <td>81.8</td> <td>73.3</td> <td>0.3</td> </tr> </tbody> </table> <p>Third/booster dose is recommended for females 12y+, males 30y+ and high-risk individuals.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)	12+	86.8	81.9	6.0	12-15	75.0	64.8	0.2	16-19	81.8	73.3	0.3
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)															
12+	86.8	81.9	6.0															
12-15	75.0	64.8	0.2															
16-19	81.8	73.3	0.3															
Infections by age group <sup>42</sup>	Hospitalisations in children <sup>43</sup>	Deaths by age group <sup>44</sup>																
<p>Infections by age group (14-day average)</p> <p>Legend:              Pink (unvaccinated)              Dark blue (1 dose)              Light blue (2 doses)</p>	<p>Incidence of hospitalisation by age group (14-day average)</p> <p>Legend:              Pink (unvaccinated)              Dark blue (1 dose)              Light blue (2 doses)</p>	<p>Deaths by age group (for the whole period)</p> <p>There have been 0 deaths in children throughout the entire pandemic</p>																

<sup>38</sup> <https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/transmission-and-protection-coronavirus>  
<sup>39</sup> <https://thl.fi/en/web/thlfi-en/-/okm-and-thl-new-covid-19-recommendations-for-early-childhood-education-and-care-educational-institutions-and-higher-education-institutions>  
<sup>40</sup> [https://sampo.thl.fi/pivot/prod/en/vaccreg/cov19cov/summary\\_cov19ageareacov](https://sampo.thl.fi/pivot/prod/en/vaccreg/cov19cov/summary_cov19ageareacov)  
<sup>41</sup> [https://www.thl.fi/episeuranta/rokotukset/koronarokotusten\\_edistyminen.html](https://www.thl.fi/episeuranta/rokotukset/koronarokotusten_edistyminen.html)  
<sup>42</sup> <https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/a-jankohtaista-koronaviruksesta-covid-19/tilannekatsaus-koronaviruksesta/koronaviruksen-seuranta>  
<sup>43</sup> <https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/a-jankohtaista-koronaviruksesta-covid-19/tilannekatsaus-koronaviruksesta/koronaviruksen-seuranta>  
<sup>44</sup> <https://experience.arcgis.com/experience/92e9bb33fac744c9a084381fc35aa3c7>



# Scotland, UK

(population 5.5 million)

PHSM <sup>45</sup>	Schools & mitigation <sup>46</sup>	Vaccination coverage <sup>47</sup>																
Mandatory masks indoors, TTIQ, screening tests, work from home encouraged	<p>Re-opened after summer holiday in mid-Sep 2021</p> <p>Standard PHSM, cohorting, mask wearing recommended for adults and students from year 7 onwards, twice-weekly RAT screening for staff and secondary school students, vaccination of 16-17y commenced mid-Aug &amp; 12-15y commenced mid-Sep 2021 (single dose)</p> <p>Close contacts who are fully vaccinated or under 18.5y and produce a negative PCR test result do not need to isolate</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> <th>3<sup>rd</sup>/booster (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>90.9</td> <td>82.6</td> <td>36.7</td> </tr> <tr> <td>12-15</td> <td>59.0</td> <td>1.6</td> <td>0.3</td> </tr> <tr> <td>16-17</td> <td>77.7</td> <td>21.5</td> <td>1.4</td> </tr> </tbody> </table> <p>Third/booster dose for 40y+ and other high-risk individuals, commenced Sep 2021.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)	12+	90.9	82.6	36.7	12-15	59.0	1.6	0.3	16-17	77.7	21.5	1.4
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)															
12+	90.9	82.6	36.7															
12-15	59.0	1.6	0.3															
16-17	77.7	21.5	1.4															
Infections by age group <sup>48</sup>	Hospitalisations in children <sup>49</sup>	Deaths by age group <sup>50,51</sup>																
<p>Figure 3: Seven day case rate in Scotland by age group by specimen date [6]. Refers to PCR testing only</p>	<p>Hospital admissions related to COVID-19 (3-week rolling average)</p> <p>Any admitted child who is COVID-19 positive is included, so this overestimates the number of children needing treatment for COVID-19</p>	<p>There have been 3 deaths due to COVID-19 in children aged 0-14y throughout the pandemic</p>																

<sup>45</sup> <https://www.gov.scot/coronavirus-covid-19/>  
<sup>46</sup> <https://www.gov.uk/government/publications/actions-for-schools-during-the-coronavirus-outbreak/schools-covid-19-operational-guidance>  
<sup>47</sup> <https://coronavirus.data.gov.uk/details/vaccinations?areaType=nation&areaName=Scotland>  
<sup>48</sup> <https://www.gov.scot/collections/coronavirus-covid-19-the-state-of-the-epidemic/>  
<sup>49</sup> <https://scotland.shinyapps.io/phs-covid19-education/?w=852fb58e7>  
<sup>50</sup> <https://www.gov.scot/collections/coronavirus-covid-19-the-state-of-the-epidemic/>  
<sup>51</sup> <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/general-publications/weekly-and-monthly-data-on-births-and-deaths/deaths-involving-coronavirus-covid-19-in-scotland>



# Singapore

(population 5.5 million)

PHSM <sup>52</sup>	Schools & mitigation <sup>53</sup>	Vaccination coverage <sup>54</sup>								
<p>Restrictions re-introduced on 27 Sep 2021 after temporary easing Mandatory masks indoors &amp; outdoors, TTIQ, work from home, shops open with maximum 5 people/group and digital check-in, maximum 5 guests at home</p> <p><b>Fully vaccinated*:</b> Social activities with maximum of 5 people/group</p> <p><b>Not fully vaccinated:</b> Social activities with reduced density limits</p> <p>*including those who have recovered from COVID-19 or have a negative pre-event test result within 24 hours</p>	<p>Re-opened in Jul 2021 with temporary home-based learning so exams could be undertaken without interruption; secondary schools continue to study onsite; phased return of primary schools from 11 Oct 2021</p> <p>Standard PHSM, cohorting, RAT &amp; temperature screening, mandatory masks 6y+ with exceptions, vaccination of 12y+ commenced early Jun 2021s</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>2<sup>nd</sup> dose (%)</th> <th>3<sup>rd</sup>/booster (%)</th> </tr> </thead> <tbody> <tr> <td>12+</td> <td>96.0</td> <td>87.0</td> <td>27.0</td> </tr> </tbody> </table> <p>Third/booster dose for 30y+ and other high-risk individuals from Sep 2021.</p>	Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)	12+	96.0	87.0	27.0
Age group (years)	1 <sup>st</sup> dose (%)	2 <sup>nd</sup> dose (%)	3 <sup>rd</sup> /booster (%)							
12+	96.0	87.0	27.0							
Infections by age group <sup>55</sup>	Hospitalisations in children <sup>56</sup>	Deaths by age group <sup>57</sup>								
<p><b>Number of Community Cases by Age</b></p>	<p><b>Hospitalised Patients by Age Groups</b></p> <p>One child was admitted to ICU due to MIS-C</p> <p>There have been five cases of MIS-C throughout the entire pandemic, last reported 8 Nov 2021</p>	<p><b>Deaths by Age Groups</b></p> <p>There have been 0 deaths in children throughout the entire pandemic</p>								

<sup>52</sup> <https://www.moh.gov.sg/covid-19-phase-advisory>  
<sup>53</sup> <https://www.moe.gov.sg/faqs-covid-19-infection>  
<sup>54</sup> <https://www.moh.gov.sg/>  
<sup>55</sup> <https://www.moh.gov.sg/>  
<sup>56</sup> <https://www.moh.gov.sg/covid-19/statistics>  
<sup>57</sup> <https://www.moh.gov.sg/covid-19/statistics>





# USA

(population 332.8 million)

PHSM <sup>58</sup>	Schools & mitigation <sup>59</sup>	Vaccination coverage <sup>60,61</sup>																
<p>Varies by state</p> <p>The US CDC recommends indoor mask wearing for all unvaccinated and aged 2y+, physical distancing, hand &amp; surface hygiene, TTIQ, but adoption varies by State</p>	<p>Many schools have reopened from Sep 2021</p> <p>Standard PHSM, cohorting, masks, PCR &amp; RAT screening, vaccination commenced mid-May for 12+ and early Nov 2021 for 5-11y, but adoption varies by State</p>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>Fully vaccinated* (%)</th> <th>3<sup>rd</sup>/booster (%)</th> </tr> </thead> <tbody> <tr> <td>5-11</td> <td>15.5</td> <td>2.2</td> <td>-</td> </tr> <tr> <td>12-17</td> <td>61.3</td> <td>51.5</td> <td>-</td> </tr> <tr> <td>18+</td> <td>81.0</td> <td>71.3</td> <td>23.3</td> </tr> </tbody> </table> <p>*Note: The US also uses the J&amp;J/Janssen vaccine which is a single-dose vaccine. Third/booster dose for 65y+ and other high-risk individuals from Sep 2021, expanded to all 18y+ from late Nov 2021.</p>	Age group (years)	1 <sup>st</sup> dose (%)	Fully vaccinated* (%)	3 <sup>rd</sup> /booster (%)	5-11	15.5	2.2	-	12-17	61.3	51.5	-	18+	81.0	71.3	23.3
Age group (years)	1 <sup>st</sup> dose (%)	Fully vaccinated* (%)	3 <sup>rd</sup> /booster (%)															
5-11	15.5	2.2	-															
12-17	61.3	51.5	-															
18+	81.0	71.3	23.3															
Infections by age group <sup>62</sup>	MIS-C <sup>63</sup>	Deaths by age group <sup>64,65</sup>																
<p>COVID-19 Weekly Cases per 100,000 Population by Age Group, United States March 01, 2020 - December 04, 2021*</p>	<p>Daily MIS-C Cases and COVID-19 Cases Reported to CDC (7-Day Moving Average)</p>	<p>COVID-19 Weekly Deaths per 100,000 Population by Age Group, United States March 01, 2020 - December 04, 2021*</p>																
Hospitalisations in children <sup>66</sup>																		
<p>Any admitted child who is COVID-19 positive is likely to be included, so this is likely an overestimation of the number of children needing treatment for COVID-19</p>	<p>MIS-C Patients By Age Group</p> <p>There have been 5973 cases of MIS-C throughout the entire pandemic, including 52 deaths The median age of patients with MIS-C was 9y and half were between 5-13y</p>	<p>Total 630 deaths with COVID-19 in children 0-17y throughout the entire pandemic Deaths in children account for &lt;0.2% of all deaths in the US</p>																

<sup>58</sup> <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html>  
<sup>59</sup> <https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-guidance.html>  
<sup>60</sup> [https://covid.cdc.gov/covid-data-tracker/#vaccinations\\_vacc-total-admin-rate-total](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total)  
<sup>61</sup> <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends>  
<sup>62</sup> <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>  
<sup>63</sup> <https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance>  
<sup>64</sup> <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>  
<sup>65</sup> [https://www.cdc.gov/nchs/nvss/vsrr/covid\\_weekly/index.htm](https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm)  
<sup>66</sup> [https://gis.cdc.gov/grasp/COVIDNet/COVID19\\_3.html](https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html)





## USA: Comparison of states

A comparison of select US states based on 7-day incidence per 100,000 population and PHSM

INDICATOR	MONTANA (pop. 1.1 million)	TENNESSEE (pop. 6.8 million)	CALIFORNIA (pop. 39.5 million)																																				
<b>7-day incidence per 100,000 population<sup>67</sup></b>	179.2	127.8	74.2																																				
<b>PHSM</b>	Mask wearing encouraged, physical distancing, TTIQ <sup>68</sup>	Mask wearing encouraged, physical distancing, TTIQ <sup>69</sup>	Indoor mask wearing mandatory in many indoor venues for all aged 2+, TTIQ <sup>70</sup>																																				
<b>Schools &amp; mitigation</b>	Schools reopened from Aug 2021 Standard PHSM as recommended by US CDC, school-based mask mandates with option for parents to opt-out, vaccination encouraged, vaccination of 12+y commenced mid-May 2021 <sup>71</sup>	Schools reopened from Aug 2021 Standard PHSM as recommended by US CDC, mask wearing and vaccination encouraged, vaccination of 12+y commenced mid-May 2021 <sup>72</sup>	Schools reopened from Sep 2021 Standard PHSM as recommended by US CDC, mask wearing mandatory for all aged 2+, PCR & RAT screening, vaccination of 12+y commenced mid-May 2021, mandatory staff vaccination or weekly testing <sup>73</sup>																																				
<b>Vaccination coverage<sup>74</sup></b>	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>Fully vacc.* (%)</th> </tr> </thead> <tbody> <tr> <td>12-17</td> <td>46.1</td> <td>38.8</td> </tr> <tr> <td>18-64</td> <td>63.5</td> <td>55.5</td> </tr> <tr> <td>65+</td> <td>99.3</td> <td>90.2</td> </tr> </tbody> </table>	Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)	12-17	46.1	38.8	18-64	63.5	55.5	65+	99.3	90.2	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>Fully vacc.* (%)</th> </tr> </thead> <tbody> <tr> <td>12-17</td> <td>40.2</td> <td>33.3</td> </tr> <tr> <td>18-64</td> <td>63.0</td> <td>54.9</td> </tr> <tr> <td>65+</td> <td>94.5</td> <td>86.7</td> </tr> </tbody> </table>	Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)	12-17	40.2	33.3	18-64	63.0	54.9	65+	94.5	86.7	<table border="1"> <thead> <tr> <th>Age group (years)</th> <th>1<sup>st</sup> dose (%)</th> <th>Fully vacc.* (%)</th> </tr> </thead> <tbody> <tr> <td>12-17</td> <td>75.1</td> <td>61.0</td> </tr> <tr> <td>18-64</td> <td>87.8</td> <td>72.4</td> </tr> <tr> <td>65+</td> <td>99.9</td> <td>90.5</td> </tr> </tbody> </table>	Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)	12-17	75.1	61.0	18-64	87.8	72.4	65+	99.9	90.5
Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)																																					
12-17	46.1	38.8																																					
18-64	63.5	55.5																																					
65+	99.3	90.2																																					
Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)																																					
12-17	40.2	33.3																																					
18-64	63.0	54.9																																					
65+	94.5	86.7																																					
Age group (years)	1 <sup>st</sup> dose (%)	Fully vacc.* (%)																																					
12-17	75.1	61.0																																					
18-64	87.8	72.4																																					
65+	99.9	90.5																																					
	*The US also uses the J&J/Janssen vaccine which is a single-dose vaccine. State-specific data on 3 <sup>rd</sup> /booster dose coverage not available.																																						

<sup>67</sup> [https://covid.cdc.gov/covid-data-tracker/#cases\\_casesper100klast7days](https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days)

<sup>68</sup> <https://covid19.mt.gov/index>

<sup>69</sup> <https://covid19.tn.gov/prevention/>

<sup>70</sup> <https://covid19.ca.gov/masks-and-ppe/>

<sup>71</sup> <https://dphhs.mt.gov/publichealth/cdepi/diseases/CoronavirusMT/index>

<sup>72</sup> <https://www.tn.gov/health/cedep/ncov/educational-resources.html>

<sup>73</sup> <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/K-12-Guidance-2021-22-School-Year.aspx>


<sup>74</sup> <https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker>





INDICATOR	MONTANA (pop. 1.1 million)	TENNESSEE (pop. 6.8 million)	CALIFORNIA (pop. 39.5 million)
<p><b>Infections by age group<sup>75</sup></b></p>	<p><b>COVID-19 Weekly Cases per 100,000 Population by Age Group, United States</b> March 01, 2020 - December 04, 2021*</p>	<p><b>COVID-19 Weekly Cases per 100,000 Population by Age Group, United States</b> March 01, 2020 - December 04, 2021*</p>	<p><b>COVID-19 Weekly Cases per 100,000 Population by Age Group, United States</b> March 01, 2020 - December 04, 2021*</p>
<p><b>Hospitalisations in children<sup>77</sup></b></p>	<p><b>New Admissions of Patients with Confirmed COVID-19 per 100,000 Population by Age Group, Montana</b> Aug 01, 2020 - Nov 30, 2021</p> <p>Montana   0 - 17 Years</p> <p>1 Total Admissions: Aug 01, 2020 - Nov 30, 2021</p> <p>1 Current 7-Day Average: Nov 24, 2021 - Nov 30, 2021</p> <p>1 Peak 7-Day Average: Nov 17, 2021 - Nov 23, 2021</p> <p>8 Peak 7-Day Average: Sep 26, 2020 - Oct 02, 2020</p> <p>-11.1% Percent change from prior 7-day avg. (Sep 26, 2020 - Nov 30, 2021)</p> <p>-84.9% Percent change from peak 7-day avg. (Sep 26, 2020 - Oct 02, 2020)</p>	<p><b>New Admissions of Patients with Confirmed COVID-19 per 100,000 Population by Age Group, Tennessee</b> Aug 01, 2020 - Nov 30, 2021</p> <p>Tennessee   0 - 17 Years</p> <p>1,540 Total Admissions: Aug 01, 2020 - Nov 30, 2021</p> <p>2 Current 7-Day Average: Nov 24, 2021 - Nov 30, 2021</p> <p>17 Peak 7-Day Average: Aug 26, 2020 - Sep 02, 2020</p> <p>-18.8% Percent change from prior 7-day avg. (Aug 26, 2020 - Nov 30, 2021)</p> <p>-89.0% Percent change from peak 7-day avg. (Aug 26, 2020 - Sep 02, 2020)</p>	<p><b>San Francisco<sup>76</sup> (pop. 882,000):</b></p> <p><b>COVID19 Cases by Age Groups</b> Age Groups: 0-11 years, 12-17 years, 18+ years</p> <p><b>New Admissions of Patients with Confirmed COVID-19 per 100,000 Population by Age Group, California</b> Aug 01, 2020 - Nov 30, 2021</p> <p>California   0 - 17 Years</p> <p>5,506 Total Admissions: Aug 01, 2020 - Nov 30, 2021</p> <p>7 Current 7-Day Average: Nov 24, 2021 - Nov 30, 2021</p> <p>11 Peak 7-Day Average: Nov 17, 2021 - Nov 23, 2021</p> <p>29 Peak 7-Day Average: Sep 26, 2020 - Oct 02, 2020</p> <p>-36.7% Percent change from prior 7-day avg. (Sep 26, 2020 - Nov 30, 2021)</p> <p>-75.6% Percent change from peak 7-day avg. (Sep 26, 2020 - Oct 02, 2020)</p>

<sup>75</sup> <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>  
<sup>76</sup> <https://sf.gov/information/updated-data-covid-19-cases-among-san-francisco-children-and-schools>  
<sup>77</sup> <https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions>




Note: Comparative graphs may have different scales on the y-axis.

<sup>78</sup> <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>



# USA: Impact of vaccination on disease incidence

Seven-day incidence per 100,000 population in people who received at least one dose of vaccine, by age group<sup>79</sup>



<sup>79</sup> <https://covid.cdc.gov/covid-data-tracker/#vaccinations-cases-trends>



## Authors

**Darren Suryawijaya Ong**

Research Assistant, Asia-Pacific Health, Murdoch Children's Research Institute

**Dr John Hart**

Research Clinician, Asia-Pacific Health, Murdoch Children's Research Institute

**Professor Fiona Russell**

Director, Child and Adolescent Health PhD Program, Department of Paediatrics, The University of Melbourne  
Group Leader, Asia-Pacific Health, Murdoch Children's Research Institute